TECH Bio-Techne Corporation Stock Quote

TECH [NASD]

Index	-	P/E	94.46	EPS (ttm)	4.39	Insider Own	0.50%	Shs Outstand	38.69M	Perf Week	2.84%
Market Cap	15.95B	Forward P/E	58.19	EPS next Y	7.12	Insider Trans	-45.01%	Shs Float	38.59M	Perf Month	10.83%
Income	174.80M	PEG	6.30	EPS next Q	1.55	Inst Own	94.30%	Short Float	1.00%	Perf Quarter	19.21%
Sales	799.00M	P/S	19.97	EPS this Y	135.60%	Inst Trans	-0.67%	Short Ratio	1.86	Perf Half Y	56.09%
Book/sh	39.34	P/B	10.54	EPS next Y	16.67%	ROA	8.60%	Target Price	422.78	Perf Year	93.86%
Cash/sh	7.35	P/C	56.40	EPS next 5Y	15.00%	ROE	12.40%	52W Range	200.09 - 423.09	Perf YTD	30.53%
Dividend	1.28	P/FCF	105.52	EPS past 5Y	15.00%	ROI	6.30%	52W High	-2.47%	Beta	1.11
Dividend %	0.31%	Quick Ratio	3.70	Sales past 5Y	10.30%	Gross Margin	66.60%	52W Low	106.23%	ATR	13.01
Employees	2300	Current Ratio	4.60	Sales Q/Q	-39.10%	Oper. Margin	23.40%	RSI (14)	59.71	Volatility	2.65% 3.21%
Optionable	Yes	Debt/Eq	0.15	EPS Q/Q	-66.20%	Profit Margin	21.90%	Rel Volume	0.70	Prev Close	414.51
Shortable	Yes	LT Debt/Eq	0.14	Earnings	May 06 BMO	Payout	28.20%	Avg Volume	207.02K	Price	412.65
Recom	1.80	SMA20	4.48%	SMA50	7.01%	SMA200	32.97%	Volume	113,463	Change	-0.45%

Mar-08-21

Upgrade

Stephens

Equal-Weight → Overweight

$380 → $425

Feb-23-21

Upgrade

Stifel

Hold → Buy

$435

Jan-25-21

Reiterated

The Benchmark Company

Buy

$320 → $410

Nov-10-20

Initiated

KeyBanc Capital Markets

Sector Weight

$340

Sep-30-20

Initiated

Atlantic Equities

Overweight

$365

Jul-15-20

Downgrade

Stephens

Overweight → Equal-Weight

May-27-20

Downgrade

Stifel

Buy → Hold

$245 → $260

May-14-20

Initiated

The Benchmark Company

Buy

$290

Jan-08-20

Resumed

Stephens

Overweight

$250

Jan-08-20

Initiated

Wells Fargo

Equal Weight

$230

Jan-07-20

Initiated

Citigroup

Neutral

$235

Nov-15-19

Initiated

Stifel

Buy

Jul-02-19

Upgrade

Janney

Neutral → Buy

$200 → $270

Jan-14-19

Upgrade

Stephens

Equal-Weight → Overweight

Oct-31-18

Downgrade

Craig Hallum

Buy → Hold

Oct-17-18

Initiated

Goldman

Neutral

$190

Jun-15-18

Initiated

Argus

Buy

$185

Jul-13-17

Initiated

Wells Fargo

Market Perform

Feb-09-17

Initiated

Citigroup

Buy

$115

Jan-18-17

Initiated

Deutsche Bank

Buy

$115

Apr-19-21 12:53PM	Is Bio-Techne Corporation (TECH) A Smart Long-Term Buy? Insider Monkey
Apr-15-21 07:49AM	The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split Benzinga
07:00AM	Bio-Techne Announces Launch of Professional Assay Services - Dedicated Source for RNA in situ Hybridization Assays in Spatial Gene Expression Analysis PR Newswire
Apr-14-21 07:00AM	Bio-Techne Announces Licensing of Proprietary Antibody to Xencor for Therapeutic Development PR Newswire
Apr-08-21 07:00AM	Bio-Techne Announces Commercial Release of Abby Automated Western System for Simple Western and Introduces Stellar Modules for Jess PR Newswire
Apr-06-21 04:01PM	Bio-Techne Completes Acquisition of Asuragen, Inc. PR Newswire
07:00AM	Bio-Techne To Host Conference Call On May 6, 2021 To Announce Third Quarter 2021 Financial Results PR Newswire
Mar-29-21 07:00AM	Bio-Techne Announces Launch of Cultrex UltiMatrix BME to Support Organoid and Pluripotent Stem Cell Cultures PR Newswire -5.47%
Mar-26-21 07:00AM	Bio-Techne Announces Receipt of COVID-19 Innovation Award from CiteAb PR Newswire
Mar-23-21 07:00AM	Bio-Techne's Exosome Diagnostics Laboratory Announces CE-IVD Certification For ExoDx Prostate Test PR Newswire
Mar-15-21 07:00AM	Bio-Techne Announces ISO 9001:2015 Certification for its Bristol Manufacturing Facility. PR Newswire
Mar-11-21 12:54PM	Is Bio-Techne (TECH) A Smart Long-Term Buy? Insider Monkey +6.67%
Mar-10-21 10:31AM	Kantaro Biosciences Named to Fast Company's Annual List of the World's Most Innovative Companies for 2021 and Ranked First in the Joint Ventures Category PR Newswire
Mar-08-21 07:00AM	Bio-Techne Announces ExoTRU Kidney Transplant Rejection Assay Data Publication PR Newswire
Mar-04-21 08:12AM	The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company Benzinga
06:37AM	Bio-Techne Scoops Up Genetics And Oncology-Focused Diagnostics Firm Benzinga
Mar-03-21 04:45PM	Bio-Techne to Acquire Asuragen PR Newswire
Mar-02-21 07:00AM	Bio-Techne To Present At The Barclays Global Healthcare Conference PR Newswire
Mar-01-21 07:00AM	Bio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With Humana PR Newswire
Feb-23-21 07:00AM	Bio-Techne and Luminary Therapeutics sign license agreement for use of Bio-Techne's TcBuster for the development of Luminary's CAR-T cell therapies PR Newswire
Feb-22-21 06:53AM	Bio-Techne Corporation's (NASDAQ:TECH) Stock Is Going Strong: Is the Market Following Fundamentals? Simply Wall St.
Feb-18-21 01:15PM	Charles River Labs International Shows Improved Relative Strength; Still Shy Of Benchmark Investor's Business Daily
Feb-16-21 07:00AM	Bio-Techne To Present At Citi's 2021 Healthcare Services, Medtech, Tools & HCIT Virtual Conference PR Newswire
Feb-11-21 07:00AM	Bio-Techne Announces Paper Publication In Annals Of Oncology PR Newswire
Feb-10-21 11:31AM	FDA Adds Kantaro's Semi-Quantitative COVID-19 Antibody Test to Revised Emergency Use Authorization for Convalescent Plasma PR Newswire
07:00AM	Bio-Techne To Present At The 2021 SVB Leerink Global Healthcare Conference PR Newswire
Feb-08-21 07:30AM	Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative COVID-19 Antibody Tests in Europe and South America PR Newswire
Feb-03-21 01:00PM	Bio-Techne Stock's Composite Rating Gets Even Healthier Investor's Business Daily
07:00AM	Bio-Techne Announces Expanded Simple Plex Immunoassay Cartridge Portfolio PR Newswire
Feb-02-21 03:30PM	Bio-Techne Corp (TECH) Q2 2021 Earnings Call Transcript Motley Fool +10.79%
07:08AM	Bio-Techne: Q2 Earnings Insights Benzinga
06:45AM	Bio-Techne Corp. to Host Earnings Call ACCESSWIRE
06:30AM	Bio-Techne Releases Second Quarter Fiscal 2021 Results PR Newswire
06:30AM	Bio-Techne Declares Dividend PR Newswire
Jan-30-21 01:19PM	The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More Benzinga
Jan-28-21 07:00AM	Bio-Techne Announces Strategic Investment In Eminence PR Newswire
Jan-14-21 07:00AM	Bio-Techne To Host Conference Call On February 2, 2021 To Announce Second Quarter 2021 Financial Results PR Newswire
Jan-08-21 06:54AM	A Look At Bio-Techne's (NASDAQ:TECH) CEO Remuneration Simply Wall St.
Dec-21-20 10:03AM	Is TECH A Good Stock To Buy According To Hedge Funds? Insider Monkey
07:00AM	Bio-Techne To Present At The 39th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-09-20 03:44AM	At US$309, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely? Simply Wall St.
Dec-08-20 12:28PM	Is Bio-Techne Corp (TECH) a Smart Long-term Buy? Insider Monkey
Dec-02-20 07:00AM	Regulus Therapeutics Collaborates With Bio-Techne For Biomarker Development PR Newswire
Nov-25-20 07:30AM	Kantaro Receives FDA Emergency Use Authorization for Semi-Quantitative COVID-19 Antibody Test Kit that Detects the Presence and Level of SARS-CoV-2 IgG Antibodies PR Newswire
Nov-11-20 07:00AM	Bio-Techne To Present At The Stephens Annual Investment Conference 2020 PR Newswire
Nov-09-20 10:38AM	Bio-Techne Corporation (NASDAQ:TECH) Just Beat Earnings: Here's What Analysts Think Will Happen Next Simply Wall St.
Nov-05-20 10:01PM	Bio-Techne Corp (TECH) Q1 2021 Earnings Call Transcript Motley Fool +14.01%
06:30AM	Bio-Techne Releases First Quarter Fiscal 2021 Results PR Newswire
06:30AM	Bio-Techne Declares Dividend PR Newswire
Nov-04-20 07:00AM	Bio-Techne To Present At The Stifel 2020 Virtual Healthcare Conference PR Newswire
Nov-02-20 07:00AM	Bio-Techne To Present At The 29th Annual Credit Suisse Virtual Healthcare Conference PR Newswire
Oct-28-20 07:30AM	EKF and Kantaro Partner to Market Quantitative COVID-19 Antibody Testing in the UK and Europe PR Newswire
Oct-26-20 07:30AM	CE Mark Approval Granted to Kantaro COVID-SeroKlir and COVID-SeroIndex Quantitative Antibody Test Kits PR Newswire
Oct-19-20 07:00AM	Bio-Techne Announces Commercial Release Of New SARS-CoV-2 Multi-Antigen Serology Assay Kit For Simple Western PR Newswire
Oct-15-20 07:00AM	Bio-Techne Announces ISO 13485:2016 Certification for the Woburn, MA Manufacturing Facility PR Newswire
Oct-13-20 09:37AM	Can You Imagine How Jubilant Bio-Techne's (NASDAQ:TECH) Shareholders Feel About Its 180% Share Price Gain? Simply Wall St.
07:00AM	Bio-Techne To Host Conference Call On November 5, 2020 To Announce First Quarter 2021 Financial Results PR Newswire
Oct-01-20 07:00AM	Bio-Techne Announces Opening Of New Canadian Facility PR Newswire
Sep-30-20 07:00AM	Bio-Techne Announces Grand Opening Of GMP Manufacturing Facility PR Newswire
Sep-28-20 08:36PM	Do Hedge Funds Really Like Bio-Techne Corporation (TECH)? Insider Monkey
Sep-23-20 07:00AM	Bio-Techne Announces Publication Of ExoDx Prostate Test Study In Patients With Prior Negative Prostate Biopsy PR Newswire
Sep-22-20 07:00AM	Bio-Techne Announces Commercial Release Of New Co-Detection Assays For Simultaneous Detection Of RNA And Protein On The Same Sample PR Newswire
Sep-21-20 07:00AM	Bio-Techne Rebrands B-MoGen Biotechnologies As Part Of The R&D Systems Product Portfolio PR Newswire
Sep-17-20 07:00AM	Bio-Techne and QIAGEN Announce Expansion and Extension of Exosome Partnership PR Newswire
Sep-15-20 03:41PM	Top Biotech Stocks for Q4 2020 Investopedia
Sep-11-20 02:57PM	Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist? Simply Wall St.
Sep-08-20 07:00AM	Bio-Techne And Hall Of Famer Cal Ripken Jr -Announce Partnership To Raise Awareness And Education To Empower Men With Prostate Cancer PR Newswire
Sep-03-20 07:00AM	Bio-Techne To Present At The 2020 Wells Fargo Virtual Healthcare Conference PR Newswire
Aug-19-20 08:00AM	Bio-Techne Corporation and Leica Biosystems are Accelerating Disease Research with RNAscope COVID-19 Probes and the BOND RX* PR Newswire
Aug-11-20 07:00AM	Bio-Techne Announces Release of a New SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody that Blocks Viral Entry PR Newswire
Aug-06-20 06:00AM	NanoString and Bio-Techne Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler Business Wire
06:00AM	Bio-Techne And NanoString Announce Offering Of RNAscope Reagents Validated For Use With The GeoMx Digital Spatial Profiler PR Newswire
Aug-04-20 03:31PM	Bio-Techne Corp (TECH) Q4 2020 Earnings Call Transcript Motley Fool
07:25AM	Recap: Bio-Techne Q4 Earnings Benzinga
07:20AM	Bio-Techne Corporation's (NASDAQ:TECH) Stock Is Going Strong: Is the Market Following Fundamentals? Simply Wall St.
06:30AM	Bio-Techne Releases Fourth Quarter Fiscal 2020 Results PR Newswire
06:30AM	Bio-Techne Declares Dividend PR Newswire
Aug-03-20 07:00AM	Bio-Techne Announces Appointment Of Julie L. Bushman To Its Board Of Directors PR Newswire
07:00AM	Bio-Techne And Kantaro Biosciences To Launch A Quantitative Research Use Only COVID-19 Serology Test PR Newswire
Jul-22-20 11:23AM	Five Companies Reach 52-Week Highs GuruFocus.com
Jul-21-20 07:09PM	Earnings Season Watch List: Bio-Techne Nears Buy Point Investor's Business Daily
07:00AM	Bio-Techne Announces Launch Of ExoCovid-19 Test For Detection Of SARS-CoV-2 In Patient Samples PR Newswire
Jul-20-20 07:00AM	Bio-Techne Announces Commercial Release Of New Assay For Detecting ASOs, miRNAs, And siRNAs In Tissue PR Newswire
Jul-13-20 10:09AM	Did Hedge Funds Make The Right Call On Bio-Techne Corporation (TECH) ? Insider Monkey
07:00AM	Bio-Techne To Host Conference Call On August 4, 2020 To Announce Fourth Quarter 2020 Financial Results PR Newswire
Jun-11-20 07:00AM	Bio-Techne And ZERO - The End Of Prostate Cancer Announce Partnership To Fund Education And Awareness Campaigns To Empower Men With Prostate Cancer PR Newswire -7.62%
Jun-09-20 07:00AM	Bio-Techne Continues to Expand Its Portfolio to Support SARS-CoV-2 and COVID-19 Research and Therapeutic Development PR Newswire
Jun-08-20 12:51PM	Hedge Funds Are Done Buying Bio-Techne Corporation (TECH)? Insider Monkey
07:00AM	Bio-Techne Announces Release of GMP ProDots Proteins to Support Cell and Gene Therapy Manufacturing Workflows PR Newswire
Jun-04-20 10:20AM	A 50-year technological revolution is about to begin. These are the stocks to own, says strategist MarketWatch
May-27-20 07:00AM	Bio-Techne To Present At The Jefferies Virtual Healthcare Conference PR Newswire
May-26-20 03:00AM	Leica Biosystems and Bio-Techne Announce European Launch of the CE-IVD RNAscope In Situ Hybridization Detection Kit PR Newswire
May-25-20 11:37AM	A Rising Share Price Has Us Looking Closely At Bio-Techne Corporation's (NASDAQ:TECH) P/E Ratio Simply Wall St.
May-20-20 08:12AM	The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test Benzinga
May-19-20 04:05PM	Bio-Techne And Kantaro Biosciences Announce Partnership To Develop And Scale Production Of COVID-19 Serology Test PR Newswire
May-18-20 06:00PM	Edited Transcript of TECH earnings conference call or presentation 30-Apr-20 1:00pm GMT Thomson Reuters StreetEvents
May-11-20 11:32AM	A Rising Share Price Has Us Looking Closely At Bio-Techne Corporation's (NASDAQ:TECH) P/E Ratio Simply Wall St.
May-07-20 10:35AM	Bio-Techne Announces Publication of ExoDx Prostate (IntelliScore) EPI Test Clinical Utility Study PR Newswire
May-04-20 01:26PM	Bio-Techne Corporation Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next Simply Wall St.
Apr-30-20 08:30PM	Bio-Techne Corp (TECH) Q3 2020 Earnings Call Transcript Motley Fool +6.54%

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kummeth Charles R.	Chief Executive Officer	Feb 16	Option Exercise	94.35	30,000	2,830,500	176,269	Feb 18 04:38 PM
Furlow Brenda S.	SVP - General Counsel	Feb 12	Option Exercise	106.59	10,000	1,065,900	16,124	Feb 17 04:42 PM
Hippel James	Chief Financial Officer	Feb 12	Option Exercise	106.59	10,000	1,065,900	19,137	Feb 17 04:46 PM
Hippel James	Chief Financial Officer	Feb 12	Sale	400.39	10,000	4,003,908	9,137	Feb 17 04:46 PM
Furlow Brenda S.	SVP - General Counsel	Feb 12	Sale	398.64	10,000	3,986,352	6,124	Feb 17 04:42 PM
Nusse Roeland	Director	Feb 08	Option Exercise	67.47	6,000	404,850	12,765	Feb 10 04:26 PM
Nusse Roeland	Director	Feb 08	Sale	385.08	6,000	2,310,481	6,765	Feb 10 04:26 PM
Eansor Norman David	President-Protein Sciences	Feb 05	Option Exercise	106.59	32,933	3,510,328	34,251	Feb 09 05:24 PM
Kelderman Kim	Pres. Diagnostics & Genom	Feb 05	Sale	388.45	823	319,694	845	Feb 09 06:31 PM
Eansor Norman David	President-Protein Sciences	Feb 05	Sale	380.68	32,933	12,537,023	1,318	Feb 09 05:24 PM
Kummeth Charles R.	Chief Executive Officer	Jan 15	Sale	344.00	20,000	6,880,000	146,269	Jan 20 04:42 PM
Hippel James	Chief Financial Officer	Jan 11	Option Exercise	106.59	10,000	1,065,900	19,137	Jan 13 05:18 PM
Hippel James	Chief Financial Officer	Jan 11	Sale	333.63	10,000	3,336,322	9,137	Jan 13 05:18 PM
Kummeth Charles R.	Chief Executive Officer	Dec 07	Sale	308.00	5,000	1,540,000	166,269	Dec 09 04:28 PM
Furlow Brenda S.	SVP - General Counsel	Nov 30	Option Exercise	106.59	11,795	1,257,229	16,981	Dec 02 06:01 PM
Furlow Brenda S.	SVP - General Counsel	Nov 30	Sale	301.94	10,857	3,278,126	6,124	Dec 02 06:01 PM
BAUMGARTNER ROBERT V	Director	Nov 18	Option Exercise	66.90	5,000	334,500	14,612	Nov 20 04:29 PM
BAUMGARTNER ROBERT V	Director	Nov 18	Sale	303.33	5,000	1,516,675	9,612	Nov 20 04:29 PM
Hippel James	Chief Financial Officer	Nov 11	Option Exercise	106.59	7,391	787,807	16,528	Nov 12 06:59 PM
Hippel James	Chief Financial Officer	Nov 11	Sale	307.05	7,391	2,269,429	9,137	Nov 12 06:59 PM
Hippel James	Chief Financial Officer	Nov 09	Option Exercise	106.59	3,600	383,724	12,737	Nov 12 06:59 PM
Seth Alpna	Director	Nov 09	Option Exercise	145.75	5,023	732,118	7,162	Nov 19 12:27 PM
Seth Alpna	Director	Nov 09	Sale	306.62	5,023	1,540,167	2,139	Nov 19 12:27 PM
Hippel James	Chief Financial Officer	Nov 09	Sale	309.79	3,600	1,115,251	9,137	Nov 12 06:59 PM
HIGGINS JOHN L	Director	Nov 06	Option Exercise	70.35	5,000	351,750	9,412	Nov 10 04:53 PM
STEER RANDOLPH C	Director	Nov 06	Option Exercise	68.62	10,000	686,250	15,112	Nov 10 06:00 PM
Kummeth Charles R.	Chief Executive Officer	Nov 06	Option Exercise	86.25	25,157	2,169,791	186,644	Nov 10 06:04 PM
STEER RANDOLPH C	Director	Nov 06	Sale	301.99	10,000	3,019,948	5,112	Nov 10 06:00 PM
HIGGINS JOHN L	Director	Nov 06	Sale	300.35	5,000	1,501,744	4,412	Nov 10 04:53 PM
Hippel James	Chief Financial Officer	Nov 05	Option Exercise	108.49	8,809	955,688	17,946	Nov 06 04:47 PM
Hippel James	Chief Financial Officer	Nov 05	Sale	286.12	8,809	2,520,457	9,137	Nov 06 04:47 PM
Hippel James	Chief Financial Officer	Nov 04	Option Exercise	108.49	7,100	770,279	16,237	Nov 06 04:47 PM
Hippel James	Chief Financial Officer	Nov 04	Sale	274.00	7,100	1,945,427	9,137	Nov 06 04:47 PM
Eansor Norman David	President-Protein Sciences	Aug 09	Option Exercise	0.00	2,174	0	2,174	Aug 11 06:21 PM
Furlow Brenda S.	SVP - General Counsel	Aug 09	Option Exercise	0.00	1,724	0	6,035	Aug 11 06:22 PM
Kummeth Charles R.	Chief Executive Officer	Aug 09	Option Exercise	0.00	21,291	0	173,774	Aug 11 06:20 PM
Hippel James	Chief Financial Officer	Aug 09	Option Exercise	0.00	4,438	0	11,321	Aug 11 06:21 PM
Furlow Brenda S.	SVP - General Counsel	Jul 09	Option Exercise	108.49	9,079	984,981	13,390	Jul 13 04:02 PM
Furlow Brenda S.	SVP - General Counsel	Jul 09	Sale	275.76	9,079	2,503,652	4,311	Jul 13 04:02 PM
Hippel James	Chief Financial Officer	Jul 07	Option Exercise	108.49	2,577	279,579	11,884	Jul 08 05:47 PM
Hippel James	Chief Financial Officer	Jul 07	Sale	271.43	2,577	699,482	9,307	Jul 08 05:47 PM
Hippel James	Chief Financial Officer	Jul 06	Option Exercise	108.49	21,502	2,332,752	30,809	Jul 08 05:47 PM
Hippel James	Chief Financial Officer	Jul 06	Sale	271.61	21,502	5,840,152	9,307	Jul 08 05:47 PM
WIENS HAROLD J	Director	May 29	Option Exercise	101.19	3,985	403,242	8,828	Jun 02 05:13 PM
Eansor Norman David	President-Protein Sciences	May 29	Option Exercise	108.49	7,909	858,047	7,909	Jun 01 05:58 PM
Eansor Norman David	President-Protein Sciences	May 29	Sale	262.00	7,909	2,072,140	0	Jun 01 05:58 PM
WIENS HAROLD J	Director	May 29	Sale	260.00	3,985	1,036,100	4,843	Jun 02 05:13 PM
Furlow Brenda S.	SVP - General Counsel	May 28	Option Exercise	105.51	7,595	801,358	10,306	Jun 01 05:58 PM
Eansor Norman David	President-Protein Sciences	May 28	Option Exercise	108.49	3,448	374,074	3,448	Jun 01 05:58 PM
Eansor Norman David	President-Protein Sciences	May 28	Sale	260.19	3,448	897,134	0	Jun 01 05:58 PM
Furlow Brenda S.	SVP - General Counsel	May 28	Sale	260.14	5,995	1,559,533	4,311	Jun 01 05:58 PM
Kummeth Charles R.	Chief Executive Officer	May 26	Option Exercise	86.25	21,159	1,824,964	151,148	May 28 05:41 PM
Eansor Norman David	President-Protein Sciences	May 22	Option Exercise	104.04	12,600	1,310,937	12,600	May 26 05:13 PM
Eansor Norman David	President-Protein Sciences	May 22	Sale	267.93	12,600	3,375,926	0	May 26 05:13 PM
BAUMGARTNER ROBERT V	Director	May 21	Option Exercise	70.35	5,000	351,750	14,221	May 26 05:13 PM
Eansor Norman David	President-Protein Sciences	May 21	Option Exercise	94.35	11,037	1,041,341	11,037	May 26 05:13 PM
BAUMGARTNER ROBERT V	Director	May 21	Sale	266.42	5,000	1,332,117	9,221	May 26 05:13 PM
Eansor Norman David	President-Protein Sciences	May 21	Sale	267.49	11,037	2,952,316	0	May 26 05:13 PM
WIENS HAROLD J	Director	May 06	Option Exercise	87.34	4,260	372,068	9,481	May 08 04:17 PM
WIENS HAROLD J	Director	May 06	Sale	250.00	4,260	1,065,000	5,221	May 08 04:17 PM
WIENS HAROLD J	Director	Apr 30	Option Exercise	91.78	4,000	367,120	9,221	May 04 04:35 PM
WIENS HAROLD J	Director	Apr 30	Sale	225.00	4,000	900,000	5,221	May 04 04:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience